Januvia, the new diabetes treatment from Merck, has received a positive verdict from the Committee for Medicinal Products for Human Use (CHMP.) The CHMP is part of the European Medicines Evaluation Agency (EMEA.) The CHMP has recommended that Januvia be approved in the European Union to treat type 2 diabetes.
Januvia will now be submitted to the European Commission with an opinion attached. Januvia could then become the first and solo approved prescription drug in the DPP-4 inhibitor class. Merck are expected to await news of the decision with baited breath. A positive verdict will be good news for the diabetic community and healthcare services also.
If successful, the decision will apply across 27 countries. Approval for marketing is likely to be granted in April. In order to reach the decisio, the CHMP reviewed as much data as possible, based on clinical trials involving 4000 people.
Januvia should not be used by those patients who have type 1 diabetes or amongst those who have ketoacidosis. Merck and co operates in most countries as Merck, Sharp and Dohme.

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Coronavirus: UK instructed to stay at home this weekend

Health Secretary Matt Hancock has said that staying at home this weekend…

Public Health England considers low carb approach for type 2 diabetes

The low carb approach is being considered by the government to be…

Twice daily dairy intakes could reduce type 2 diabetes risk

Eating cheese, yoghurt or eggs twice a day could help lower the…